Climb Bio Inc
NASDAQ:CLYM

Watchlist Manager
Climb Bio Inc Logo
Climb Bio Inc
NASDAQ:CLYM
Watchlist
Price: 4.25 USD -8.01% Market Closed
Market Cap: 289.8m USD

Operating Margin
Climb Bio Inc

0%
Current
0%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-56.1m
/
Revenue
0

Operating Margin Across Competitors

No Stocks Found

Climb Bio Inc
Glance View

Market Cap
289.8m USD
Industry
Biotechnology

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.

CLYM Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-56.1m
/
Revenue
0
What is the Operating Margin of Climb Bio Inc?

Based on Climb Bio Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top